CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 62 enrolled
Drug / intervention
erlotinib [Tarceva]drug
Likely dose
erlotinib [Tarceva] 150 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01609543
NCT01609543Phase 4Completed
CompareCT.gov

Open Label Study of Erlotinib (Tarceva®) as Single Agent First Line Treatment of Patients With Locally Advanced or Metastatic Lung Adenocarcinoma With Activating Epidermal Growth Factor Receptor (EGFR) Mutations

Hoffmann-La Roche·interventional·Posted Jun 1, 2012·Updated Feb 1, 2016

In Brief

A Phase 4 clinical trial evaluating erlotinib [Tarceva] for Non-Squamous Non-Small Cell Lung Cancer. Completed, enrolled 62 participants across 23 sites in 3 countries.

Detailed Summary

This open-label, non-randomized, one-arm study will evaluate the safety and efficacy of Tarceva (erlotinib) as single-agent first-line treatment in patients with locally advanced or metastatic non-small cell lung cancer who show epidermal growth factor receptor (EGFR) activating mutations. Patients will receive Tarceva 150 mg orally daily until disease progression or unacceptable toxicity occurs.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsNon-Squamous Non-Small Cell Lung Cancer
CountriesHungary, Latvia, Turkey (Türkiye)
Collaborators--

Timeline

Phase 4CompletedFinished
201220132014201520162017201820192020202120222023202420252026
First PostedJun 1, 2012
Enrollment StartMay 1, 2012
Primary CompletionJan 1, 2015
TodayJul 2, 2026
Enrollment to primary: 2.7 yearsPosted 14.1 years ago

Interventions

erlotinib [Tarceva]drug

150 mg orally daily, until disease progression, unacceptable toxicity or withdrawal due to any reason